Trinity compound research profile
Retatrutide
An investigational multi-receptor peptide studied in metabolic and energy-balance research.
Research overview
Retatrutide is an investigational peptide designed to engage multiple metabolic hormone receptors. Research has focused on how combined receptor signaling can influence energy balance, appetite-related signaling, glucose regulation, and body-composition outcomes.
This profile is intentionally educational rather than instructional. Trinity’s Advanced Research Search should be used for the reviewed evidence summary, terminology, source context, and catalog-linked research information.
Why researchers study it
Its scientific interest comes from combining several signaling pathways in one molecule, making it useful for studying how incretin and glucagon-related pathways interact.
Human evidence summary
In a real study of 338 people over 48 weeks, people taking weekly retatrutide lost a huge amount of weight — from about 9% of body weight at the lowest dose up to about 24% at the highest dose, compared to only about 2% for people taking a fake shot (placebo). At the highest doses, somewhere between 60-83% of people lost 15% or more of their starting body weight, versus just 2% on placebo (Jastreboff, NEJM 2023). More studies have also tested it in people with type 2 diabetes and fatty liver disease, with bigger phase 3 trials still ongoing. So far, there's no data yet on long-term heart health outcomes.
Preclinical evidence summary
The existing research profile doesn't include separate animal-study details for retatrutide — the evidence gathered focuses on human trials since the drug moved fairly quickly into human testing.
Source material
Use the linked publications and records to evaluate study design, population, limitations, and relevance.